Product Launch
Lupin Launches Azilsartan Medoxomil Tablets in the United States with 180-Day Generic Exclusivity
NSE
lupin
BSE
500257
Lupin Limited has launched Azilsartan Medoxomil Tablets, 40mg and 80mg, in the United States following approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA). The company is the exclusive first-to-file applicant and is eligible for 180 days of generic drug exclusivity. The product is the bioequivalent generic version of Edarbi® and is indicated for the treatment of hypertension in adults.
PRICE-SENSITIVE TRIGGER
Event: Launch of Azilsartan Medoxomil Tablets in the U.S. market.
Type: Product Launch
Impact: Positive
Immediate Effect: The launch expands Lupin’s U.S. generics portfolio and provides a temporary competitive advantage through 180-day first-to-file generic exclusivity.
Key Metrics:
- Reference Product: Edarbi® (Azurity Pharmaceuticals, Inc.)
- Dosage Strengths:Â 40mg and 80mg
- Estimated U.S. Market Size:Â USD 53.5 Million
- Market Data Period:Â IQVIA MAT April 2026
- Exclusivity Benefit:Â 180-Day Generic Drug Exclusivity
- Market Opportunity: The reference product Edarbi® recorded estimated annual U.S. sales of approximately USD 53.5 million, providing Lupin access to a meaningful niche cardiovascular market opportunity.
What Happened ?
Lupin announced the commercial launch of Azilsartan Medoxomil Tablets in the United States after receiving approval from the U.S. Food and Drug Administration for its ANDA filing. The product is the generic equivalent of Edarbi® and is prescribed for the treatment of hypertension in adults to help lower blood pressure.
The company has secured exclusive first-to-file status, making it eligible for 180 days of generic drug exclusivity in the U.S. market. This exclusivity period can provide an initial competitive advantage before additional generic entrants enter the market.
Key Details
U.S. Product Launch and Commercial Opportunity:
- Lupin launched Azilsartan Medoxomil Tablets in 40mg and 80mg strengths in the United States.
- Product launch follows approval of the company’s ANDA by the U.S. FDA.
- The product is bioequivalent to Edarbi®.
- Indicated for treatment of hypertension in adult patients.
- Lupin holds exclusive first-to-file status for the product.
- Company is eligible for 180 days of generic drug exclusivity.
- The reference product generated approximately USD 53.5 million in annual U.S. sales according to IQVIA MAT April 2026 data.
- Launch further strengthens Lupin’s U.S. generics and cardiovascular portfolio.
Note:
- The first-to-file exclusivity period may enhance market penetration and pricing opportunity during the initial phase of commercialization before broader generic competition emerges.
Risk Analysis
Summary:
- While the launch creates a favorable commercial opportunity, actual revenue realization will depend on market uptake, pricing dynamics, physician adoption, and future generic competition following the exclusivity period.
Key Risks:
- Revenue performance depends on successful market penetration.
- Pricing pressure may increase after exclusivity expires.
- Competitive generic entries may reduce market share over time.
- Regulatory and reimbursement dynamics may affect product adoption.
- Market opportunity is limited to the size of the underlying reference product market.
Worst Case Scenario:
- Lower-than-expected prescription uptake or rapid pricing erosion after the exclusivity period could reduce the commercial benefits from the launch.
Risk Level: Medium
Company Commentary
- Lupin has launched Azilsartan Medoxomil Tablets in the U.S. market.
- The launch follows FDA approval of the company’s ANDA.
- The product is the bioequivalent generic version of Edarbi®.
- Lupin is the exclusive first-to-file applicant for the product.
- The company is eligible for 180 days of generic drug exclusivity.
- The therapy is indicated for the treatment of hypertension in adults.
Official Exchange Filing: Lupin Limited
